PROG 8- Hematopoietic Cell Transplantation and

PROG 8-造血细胞移植和

• 批准号: 7438443
• 负责人: Robert S Negrin
• 金额: $ 1.7万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-06-04 至 2010-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7438443
• 关键词: Ablation; Address; Adult; Allogenic; Ally; Antigen-Presenting Cells; Autologous; Biological; Biology; Blood; Bone Marrow Transplantation; Cancer Center; Cell Transplantation; Cell physiology; Cells; Cellular biology; Child; Childhood; Clinic; Clinical; Clinical Trials; Clinical Trials Network; Communities; Development; Engraftment; Faculty; Foundations; Goals; Graft Rejection; Grant; Guanosine Monophosphate; Hematologic Neoplasms; Hematopoietic; Hematopoietic stem cells; Immune; Immunology; Intervention; Investigation; Journals; K-Series Research Career Programs; Laboratories; Laboratory Research; Lymphoid; Malignant Neoplasms; Myeloid Progenitor Cells; Numbers; Outcome; Patients; Peer Review; Physicians; Population; Publications; Publishing; Purpose; Reaction; Research; Research Personnel; Resource Sharing; Scientist; Shared Resource Cancer Center; Stem cells; Textiles; Therapeutic; Toxic effect; Training; Translational Research; Translations; Transplantation; Treatment Protocols; Viral Tumor Antigens; Vision; base; cellular imaging; clinical application; concept; graft vs host disease; graft vs host reaction; improved; insight; member; multidisciplinary; novel; pol genes; programs; reconstitution; sialosyl-T antigen; tumor

The Program in Hematopoietic Cell Transplantation and Immune Reconstitution is a multidisciplinary effort aimed at developing a better understanding of the biological mechanisms underlying both autologous and allogeneic hematopoietic cell transplantation (HCT). Major themes of research include developing mechanistic insights into the underlying principles of stem cell engraftment, graft vs. host disease, graft vs. tumor reactions and immune reconstitution. Translation of novel concepts to the clinic derived from these more basic studies is of central importance. These goals are achieved by engaging a dynamic group of 19 investigators from four Departments supported by Program Project (two POls), investigator initiated (17 ROls), clinical trials network (U01), training (T32 and three K awards) and Foundation grants. Using the concept of translational research where new concepts and ideas are developed in the laboratory and extended to the clinic, as well as insights from the clinic with extension to the laboratory, novel avenues of research and strategies for intervention have been and continue to be explored. Since 2000, over 180 publications relevant to the goals of the Program have been published in peer-reviewed journals. This Program enlists basic scientists, physician-scientists and clinician investigators centered upon the over-riding goal of improving outcomes for patients undergoing HCT. Our vision is to explore the major mechanisms of successful transplantation including engraftment of hematopoietic stem cells, graft-vs.-tumor and graft-vs.-host reactions and enhancement of immune reconstitution through laboratory-based projects with extension to the clinic through mainly investigator initiated clinical trials. Clinical strategies have and are being developed based upon laboratory investigations to probe mechanisms of the major cellular populations including hematopoietic stem cells, myeloid and lymphoid progenitor cells, NK, T, NK-T and antigen presenting cells. This Program extensively interacts with both basic and translational investigators from a number of different Programs and is supported by all Cancer Center Shared Resources to provide a rich fabric of discovery and clinical translation.

造血细胞移植和免疫重建项目是一个多学科的项目 旨在更好地了解这两种现象背后的生物机制的努力 自体和异体造血细胞移植（HCT）。主要研究主题包括 深入了解干细胞植入、移植物与宿主的基本原理 疾病、移植物抗肿瘤反应和免疫重建。将新概念转化为临床 从这些更基础的研究中得出的结论至关重要。这些目标是通过参与 由来自四个部门的 19 名研究人员组成的充满活力的小组，由计划项目（两个 PO）支持， 研究者发起（17 ROls）、临床试验网络（U01）、培训（T32 和三个 K 奖）和 基金会拨款。使用新概念和想法的转化研究的概念 在实验室开发并延伸到临床，以及从临床延伸的见解 对于实验室来说，新的研究途径和干预策略已经并将继续存在 探索过。自 2000 年以来，已在以下国家出版了 180 多篇与该计划目标相关的出版物： 同行评审期刊。该计划招募基础科学家、医师科学家和临床医生 研究人员的首要目标是改善接受 HCT 的患者的预后。 我们的愿景是探索成功移植的主要机制，包括植入 造血干细胞、移植物抗肿瘤和移植物抗宿主反应以及增强免疫 通过基于实验室的项目进行重组，并通过主要方式扩展到诊所 研究者启动了临床试验。临床策略已经并正在基于以下基础上制定： 实验室研究以探究主要细胞群的机制，包括 造血干细胞、骨髓和淋巴祖细胞、NK、T、NK-T 和抗原呈递 细胞。该计划与来自多个领域的基础研究人员和转化研究人员进行了广泛的互动 不同的计划，并得到所有癌症中心共享资源的支持，以提供丰富的结构 发现和临床转化。